Evoke Pharma, Inc. (EVOK) Expected to Post Earnings of -$0.17 Per Share
Analysts forecast that Evoke Pharma, Inc. (NASDAQ:EVOK) will report ($0.17) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Evoke Pharma’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.19). Evoke Pharma reported earnings per share of ($0.24) during the same quarter last year, which suggests a positive year-over-year growth rate of 29.2%. The firm is scheduled to report its next quarterly earnings results on Wednesday, November 8th.
On average, analysts expect that Evoke Pharma will report full year earnings of ($0.79) per share for the current financial year, with EPS estimates ranging from ($0.83) to ($0.75). For the next financial year, analysts forecast that the firm will post earnings of $0.32 per share, with EPS estimates ranging from ($0.52) to $1.16. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last posted its quarterly earnings data on Monday, August 14th. The specialty pharmaceutical company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.15). During the same period last year, the firm earned ($0.41) earnings per share.
A number of equities analysts have recently commented on the stock. Zacks Investment Research raised shares of Evoke Pharma from a “strong sell” rating to a “hold” rating in a research note on Thursday, October 12th. Seaport Global Securities reissued a “buy” rating and issued a $10.00 target price on shares of Evoke Pharma in a research note on Friday, October 6th. HC Wainwright reissued a “buy” rating and issued a $9.00 target price on shares of Evoke Pharma in a research note on Monday, September 18th. Finally, ValuEngine downgraded shares of Evoke Pharma from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $8.50.
Evoke Pharma (EVOK) traded down 5.11% during mid-day trading on Thursday, hitting $3.53. The stock had a trading volume of 225,568 shares. Evoke Pharma has a one year low of $1.35 and a one year high of $4.55. The company’s market cap is $54.32 million. The company has a 50 day moving average price of $3.23 and a 200-day moving average price of $2.75.
ILLEGAL ACTIVITY NOTICE: “Evoke Pharma, Inc. (EVOK) Expected to Post Earnings of -$0.17 Per Share” was first posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/10/17/evoke-pharma-inc-evok-expected-to-post-earnings-of-0-17-per-share.html.
An institutional investor recently raised its position in Evoke Pharma stock. State Treasurer State of Michigan increased its position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) by 37.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 400,000 shares of the specialty pharmaceutical company’s stock after buying an additional 108,034 shares during the period. State Treasurer State of Michigan owned about 2.60% of Evoke Pharma worth $1,024,000 at the end of the most recent reporting period. Institutional investors own 12.88% of the company’s stock.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Evoke Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc. and related stocks with our FREE daily email newsletter.